Ciprofl oxacin for 7 days versus 14 days in women with acute pyelonephritis: A randomised, open-label and double-blind, placebo-controlled, non-inferiority trial

The Lancet

Volumn 380, Issue 9840, 2012, Pages 484-490

  Sandberg, Torsten ^a   Skoog, Gunilla ^b   Hermansson, Anna Bornefalk ^c   Kahlmeter, Gunnar ^d   Kuylenstierna, Nils ^e   Lannergard, Anders ^f   Otto, Gisela ^g   Settergren, Bo ^h   Ekman, Gunilla Stridh ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b Swedish Institute   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d CENTRAL HOSPITAL   (Sweden)

^e FALUN HOSPITAL   (Sweden)

^f UPPSALA UNIVERSITY   (Sweden)

^g LUND UNIVERSITY HOSPITAL   (Sweden)

^h CENTRAL HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; ANTIINFECTIVE AGENT;

ACUTE PYELONEPHRITIS; ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; ESCHERICHIA COLI; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYALGIA; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS SAPROPHYTICUS; THRUSH; TREATMENT DURATION; TREATMENT OUTCOME; ACUTE DISEASE; AGED; ANTIBIOTIC RESISTANCE; BACTERIURIA; CLINICAL TRIAL; COMMUNICABLE DISEASE; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; MICROBIOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; PYELONEPHRITIS; TREATMENT WITHDRAWAL;

ACUTE DISEASE; ADULT; AGED; ANTI-INFECTIVE AGENTS; BACTERIURIA; CIPROFLOXACIN; COMMUNITY-ACQUIRED INFECTIONS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MICROBIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; PYELONEPHRITIS; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 84864747915     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)60608-4     Document Type: Article

References (19)

1. Livermore D. Has the era of untreatable infections arrived? J Antimicrob Chemother 2009; 64 (suppl 1): i29-36.
2. Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 10: 597-602.
3. Rice LB. The Maxwell Finland lecture: for the duration-rational antibiotic administration in an era of antimicrobial resistance and Clostridium difficile. Clin Infect Dis 2008; 46: 491-96.
4. Infectious Diseases Society of America (IDSA). Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis 2011; 52 (suppl 5): S397-428.
5. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society of Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52: e103-20.
6. Stamm WE, McKevitt M, Counts GW. Acute renal infection in women: treatment with trimethoprim-sulfamethoxazole or ampicillin for two or six weeks. Ann Intern Med 1987; 160: 341-45.
7. Sandberg T, Englund G, Lincoln K, Nilsson L-G. Randomised double-blind study of norfloxacin and cefadroxil in the treatment of acute pyelonephritis. Eur J Clin Microbiol Infect Dis 1990; 9: 317-23.
8. Talan DA, Stamm WE, Hooton TM, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women. A randomized trial. JAMA 2000; 283: 1583-90.
9. D'Agostino RB Sr, Massaro JM, Sullivan LM. Non-inferiority trials: design concepts and issues-The encounters of academic consultants in statistics. Statist Med 2003; 22: 169-86.
10. Sandberg T, Alestig K, Eilard T, et al. Aminoglycosides do not improve the efficacy of cephalosporins for treatment of acute pyelonephritis in women. Scand J Infect Dis 1997; 29: 175-79.
11. van Nieuwkoop C, van't Wout JW, Spelt IC, et al. Prospective cohort study of acute pyelonephritis in adults: safety of triage towards home based oral antimicrobial treatment. J Infect 2010; 60: 114-21.
12. Edlund C, Nord CE. A review on the impact of 4-quinolones on the normal oropharyngeal and intestinal human microflora. Infection 1988; 16: 8-12.
13. Tartaglione TA, Johnson CR, Brust P, Opheim K, Hooton TM, Stamm WE. Pharmacodynamic evaluation of ofloxacin and trimethoprim-sulfamethoxazole in vaginal fluid of women treated for acute cystitis. Antimicrob Agents Chemother 1988; 32: 1640-43.
14. Jernelius H, Zbornik J, Bauer C-A. One or three weeks' treatment of acute pyelonephritis. Acta Med Scand 1988; 223: 469-77.
15. Eriksson S, Zbornik J, DahnsjH, et al. The combination of pivampicillin and pivmecillinam versus pivampicillin alone in the treatment of acute pyelonephritis. Scand J Infect Dis 1986; 18: 431-38.
16. Cronberg S, Banke S, Bergman B, et al. Fewer bacterial relapses after oral treatment with norfloxacin than with ceftibuten in acute pyelonephritis initially treated with intravenous cefuroxime. Scand J Infect Dis 2001; 33: 339-43.
17. Winberg J, Herthelius-Elman M, Mlby R, Nord CE. Pathogenesis of urinary tract infection-experimental studies of vaginal resistance to colonization. Pediatr Nephrol 1993; 7: 509-14.
18. SWEDRES (2010). A report on Swedish antibiotic utilisation and resistance in human medicine. http://www.smittskyddsinstitutet. se/publikationer/ arsrapporter-och-verksamhetsberattelser/swedres/swedres-2010 (accessed Aug 1, 2011).
19. Antimicrobial resistance surveillance in Europe 2009. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). http://www.ecdc.europa.eu/publications/Publicatins/Forms/ECDC-DispForm.aspx?ID= 580 (accessed Aug 1, 2011).